New Publication! shRNA Screen Finds Alternate Pathway for BCR-ABL1 Kinase-independent Resistance in CML

Functional Screening and Drug Target Discovery

Cellecta Inc. provides custom and contract solutions for high-throughput genetic screening needs. Our research organization focuses primarily on developing and implementing flexible and scalable broad-based screening and analysis approaches that identify the mechanisms regulating biological processes to expedite the discovery and characterization of novel therapeutic targets and drugs.

The unique capabilities of lentiviral and shRNA technologies provide a platform that enables genome-wide functional screening and the identification and validation of genes involved in critical biological and pathological responses.

Learn more about Cellecta